This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prophylactic Antibiotic in Treatment of Fingertip Amputation

This study has been completed.
Information provided by (Responsible Party):
guy rubin, HaEmek Medical Center, Israel Identifier:
First received: March 2, 2014
Last updated: July 9, 2015
Last verified: July 2015
Fingertip amputation is a common injury. Considerable controversy exists as to whether prophylactic antibiotics are necessary for this injury. The investigators goal was to compare the rate of infections among subgroups with and without prophylactic antibiotic treatment. The study hypothesis was that infection rates were similar in the two groups.

Condition Intervention
Infection Rate After Fingertip Amputation Drug: Cephazolin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Use of Prophylactic Antibiotic in Treatment of Fingertip Amputation: A Randomized Prospective Trial

Resource links provided by NLM:

Further study details as provided by guy rubin, HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • infection rate [ Time Frame: 1 month ]

Enrollment: 60
Study Start Date: January 2006
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: no antibiotic
Active Comparator: Cephazolin
Drug: Cephazolin
Other Name: Cefamezine


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • fingertip amputation with bone exposed

Exclusion Criteria:

  • under the age of 18 years
  • if the patient had diabetes
  • oncological disorder
  • immune deficiency
  • bleeding disorder
  • used steroids regularly
  • presented with a grossly contaminated wound or other injury requiring antibiotic treatment
  • were currently taking antibiotics, or had a previous allergic reaction to cephalosporins.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02077400

HaEmek medical center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

Responsible Party: guy rubin, Dr., HaEmek Medical Center, Israel Identifier: NCT02077400     History of Changes
Other Study ID Numbers: 0115-09-EMC
Study First Received: March 2, 2014
Last Updated: July 9, 2015

Additional relevant MeSH terms:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents processed this record on June 23, 2017